Delaware Signs Harm Reduction into Law — With Guardrails and a 12-Month Report Card

Delaware Governor Matt Meyer signed Senate Bill 249 on September 30, 2026, creating the state's first statutory licensing framework for harm reduction programs — and, in the same pen stroke, signed Executive Order 28, which sets the rules for how that framework may be rolled out and measured. The pairing is the story: Delaware is expanding needle exchange, naloxone distribution, drug-checking supplies and infectious disease screening while simultaneously building in phases, baselines, and a written report to the governor within 12 months.

The bill was sponsored by Senator Marie Pinkney and Representative Nnamdi Chukwuocha. It authorizes the Division of Substance Abuse and Mental Health (DSAMH), an arm of the Delaware Department of Health and Social Services (DHSS), to license and regulate harm reduction programs. It also removes the personal-use items those programs hand out — including equipment used to check the drug supply for adulterants such as fentanyl, xylazine and medetomidine — from the state's definition of drug paraphernalia, and removes criminal penalties for possessing personal-use paraphernalia.

A state that was already doing the work

Delaware is not starting from zero. DSAMH already contracts for syringe services, and the new law is described by the administration as a way to "authorize, standardize, and oversee" services that are already operating. The executive order makes that explicit: the first phase prioritizes existing syringe services and other well-established interventions, moving them from current contracts into the new licensing framework "without interruption of care."

That first phase covers the interventions with the strongest evidence base, according to the order:

• Naloxone and other opioid antagonists
• Infectious disease screening
• Drug-checking supplies
• Wound care
• Overdose education
• Safe disposal of equipment
• Linkage to treatment, housing and other services

These are the core components that the order describes as "strong and well established" — shown to reduce transmission of infectious disease, connect people to care, and save lives. The CDC's own review of syringe services programs reaches the same conclusion, finding that they reduce HIV and hepatitis C transmission without increasing illegal drug use or crime in the surrounding community.

What the guardrails actually require

The more contested parts of SB 249 — distribution of supplies for non-injection routes of use, and the removal of criminal penalties for personal-use paraphernalia — are where the executive order does its heaviest lifting. The order requires:

Written justification before any expansion. State funding for any category of supplies "for which the supporting evidence is emerging" may expand only after the DHSS Secretary issues a written determination that the preceding phase produced positive public health results without significant unintended harm.

Baselines and outcome tracking, set in advance. DHSS must establish measurable metrics and baselines before or at the outset of implementation, then monitor fatal and nonfatal overdose trends, infectious disease transmission, emergency department use (broken out by geography where appropriate), linkage to treatment and recovery, improper disposal of equipment, and youth exposure or diversion. It must also track community-safety indicators such as drug-related and property crime and public-order complaints inside program service areas, and, for the paraphernalia change, trends in arrests, prosecutions and diversions to care.

A hard look at the supply itself. The order directs the department to account for changes in the composition and toxicity of the illicit drug supply — including the spread of adulterants like xylazine and medetomidine — when interpreting its own data, and to lean on DSAMH's Overdose Response Center (near real-time drug supply and overdose trend analysis) and its Addiction Treatment Resource Center data hub.

A kill switch. If strong evidence shows a program component is contributing to increased overdose deaths, disease transmission or other identified harms, DHSS must pause, modify or discontinue that component and recommend corrective action.

Public reporting. DHSS must report in writing to the governor no later than 12 months after the regulations take effect, and at least annually after that, and present its findings to the Addiction Action Committee as a public forum. Findings are to be published in aggregate, de-identified form, with a recommendation on whether the program should be continued, modified or expanded.

The context: deaths are falling, but the supply is changing

Delaware's overdose deaths have dropped sharply. Accidental drug intoxication deaths fell from 527 in 2023 to 314 in 2025 — a reduction of more than 40% — a decline the order credits to sustained state effort while warning that it has been achieved "against an increasingly toxic and rapidly changing illicit drug supply."

The order also acknowledges the politics honestly. It notes that "members of the public, healthcare providers, individuals in recovery, and law enforcement expressed a range of views," with supporters emphasizing that harm reduction "meets vulnerable individuals where they are and opens a pathway to treatment," and with law enforcement organizations and others stressing the need for "clear pathways to recovery and for careful attention to community safety." The phased design, the order states, is intended to satisfy both.

What's next

The work now moves to regulation-writing. DHSS must draft and promulgate the licensing rules — covering sterile-supply standards, licensure criteria, program accountability, participant confidentiality, data collection and transparency — in coordination with the governor's office, then transition existing providers into the framework and stand up the evaluation described above. The first formal report to the governor is due within 12 months of the regulations taking effect, with annual reports and public findings after that.

For Delaware families, nothing changes overnight: existing syringe services, naloxone distribution and screening programs continue while the licensing rules are written.

Where to get help in Delaware

• Delaware Hope Line — 1-833-9-HOPEDE (1-833-946-7333), 24/7, connects callers to clinicians, peer specialists and crisis support
• Bridge Clinics — in-person assessments through DHSS
• HelpIsHereDE.com — DHSS's searchable treatment and resource hub
• TreatmentConnection.com — find nearby treatment providers
• Recovery Community Centers — seven statewide, including drop-in centers in Wilmington, Dover and Milford and Recovery Cafés in Wilmington, Newark and Dover, plus Recovery Hubs in Georgetown and Seaford
• Naloxone — free training, mail-order Narcan and the OpiRescueDE app are available through DHSS
• 988 — Suicide & Crisis Lifeline, for immediate crisis support
• 911 — for a suspected overdose

If you are outside Delaware, the SAMHSA National Helpline at 1-800-662-4357 is free, confidential and available 24/7, and findtreatment.gov lists licensed providers by state.